| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3902572 | Urology | 2011 | 7 Pages |
Abstract
Our data have suggested that CBD BDS reduces cholinergic-mediated contractility and that this effect is modulated by transient receptor potential vanilloid type-1 in rats but not in humans. CBD is the chemical ingredient of CBD BDS responsible for such activity. If confirmed in vivo, such results could provide a pharmacologic basis to explain, at least in part, the efficacy of Cannabis medicines in reducing incontinence episodes in patients with multiple sclerosis.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Raffaele Capasso, Gabriella Aviello, Francesca Borrelli, Barbara Romano, Matteo Ferro, Luigi Castaldo, Vittorino Montanaro, Vincenzo Altieri, Angelo A. Izzo,